CLOs on the Move

Talaris Therapeutics

www.talaristx.com

 
Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.talaristx.com
  • 201 East Jefferson Street Suite 110B
    Louisville, KY USA 40202
  • Phone: 502.569.1059

Executives

Name Title Contact Details

Similar Companies

New Hampshire Department of Resources and Economic Development

New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amisure International

Amisure International is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AVI BioPharma

AVI BioPharma, Inc. is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Amann Girrbach America

Amann Girrbach America is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.